[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355389-105":59,"doc-detail-355389-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mtap-deletion-in-oncogenesis-a-synthetic-lethality-scenario","MTAP Deletion in Oncogenesis - A Synthetic Lethality Scenario","","MTAP deletion occurs in about 10% of cancer patients and can reach much higher rates in certain tumor types, correlating with poor prognosis. Loss of MTAP leads to methylthioadenosine (MTA) accumulation that antagonizes S-adenosyl methionine (SAM) binding to PRMT5, undermining PRMT5-dependent regulation. Earlier PRMT5-targeting therapies caused dose-limiting hematologic toxicities due to limited tumor selectivity. Newer strategies exploit MTAP-deficient vulnerabilities via PRMT5-pathway inhibition, including MTA-cooperative PRMT5 inhibitors and agents that deprive PRMT5 of SAM, enabling synthetic lethality. This review summarizes mechanisms, preclinical and clinical evidence, and future directions for MTAP-deleted precision oncology therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mtap-deletion-in-oncogenesis-a-synthetic-lethality-scenario/355389/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mtap-deletion-in-oncogenesis-a-synthetic-lethality-scenario/355389.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is MTAP deletion (MTAP-del) and how common is it in cancer?","Question",{"text":112,"@type":113},"Homozygous deletions in MTAP occur in about 10% of all cancer patients, with higher frequencies in specific tumor types such as glioblastoma and mesothelioma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does MTAP deficiency create a therapeutic opportunity?",{"text":117,"@type":113},"MTAP loss causes MTA accumulation that outcompetes SAM for binding to PRMT5, altering PRMT5 activity. This creates selectivity for further PRMT5-pathway inhibition in MTAP-deleted tumor cells.",{"name":119,"@type":110,"acceptedAnswer":120},"Why did earlier PRMT5-targeted treatments have safety limitations?",{"text":121,"@type":113},"They showed high rates of dose-limiting hematologic toxicities because they lacked selectivity for tumor cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355389,1790386018,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario  \nJordi Rodon1, Melissa L. Johnson2, Ben George3, Pooja A. Shah1, and Kathryn C. Arbour4  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Homozygous deletions in the gen∼ e encoding methylthioadenosine\u003Cbr>phosphorylase (MTAP) occur in 10% of patients with cancer, including up to 45% in some tumor types, and may be associated with poor prognosis. MTAP deficiency causes accumulation of its catabolic target methylthioadenosine (MTA) that outcompetes S-adenosyl methionine (SAM) for binding to protein arginine methyltransferase 5 (PRMT5), partially inhibiting PRMT5 activity as a posttranslational regulator of a variety of critical cellular functions. Prior anticancer treatments developed to target PRMT5 exhibited high rates of dose-limiting hematologic toxicities because of a lack of selectivity for tumor cells. More recently, several agents have been developed that exploit the\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | vulnerability of MTAP-deleted cancer cells to further inhibition of the PRMT5 pathway, selectively inducing synthetic lethalityin those cancer cells. MTA-cooperative PRMT5 inhibitors such as BMS-986504/MRTX1719 and AMG 193 target the PRMT5– MTA complex, whereas inhibitors of the SAM synthetase methionine adenosyl transferase 2A, such as IDE397, deprive PRMT5 of its methyl donor SAM. In this review article, we summarize the mechanisms of action, preclinical data, and clinical data available thus far for these novel classes of oncology precision medicine and discuss potential future directions relevant to MTAP deletion as a promising synthetic lethal vulnerability for cancer therapy. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nAlthough targeted therapy and immunotherapy have greatly improved survival and quality of life compared with traditional chemotherapy treatments in cancer, the cancer burden continues to grow worldwide, with 20 million new cases and 9.7 million cancerrelated deaths in 2022 (RRID: SCR_ 025451) . As such, there is a continual pursuit for new anticancer agents that can balance efficacy with tolerability. A key approach in developing these therapies is identifying cancer-specific biomarkers and their role in oncogenesis. MTAP, encoding the enzyme methylthioadenosine phosphorylase, lies in the same gene cluster as CDKN2A, a tumor suppressor gene commonly deleted in cancer cells, and several IFN genes on the chromosome 9p21 locus (1) . Homozygous deletions in MTAP (MTAP-del) occur in approximately 10% of all patients with cancer, presumably because of its proximity to CDKN2A (RRID: SCR_003193; ref. 2) . Tumor types∼ with particularly high rates of M∼TAP-del include glioblastoma∼( 45% of patients), mesothelioma ( 36%), urothel∼ial carcinoma ( 26%), m∼alignant peripheral nervesheath tumor ( 25%), ∼pancreatic cancer ( 22%), and non–small cell  \nlung cancer (NSCLC; 15","cbCaiikU7138V3Za","https://ap.wps.com/l/cbCaiikU7138V3Za","pdf",4033585,12,"English","# Introduction\n## MTAP deletion as a cancer-specific biomarker\n## Synthetic lethality via PRMT5 pathway inhibition\n## Compounds targeting PRMT5–MTA complex and SAM depletion","[{\"question\":\"What is MTAP deletion (MTAP-del) and how common is it in cancer?\",\"answer\":\"Homozygous deletions in MTAP occur in about 10% of all cancer patients, with higher frequencies in specific tumor types such as glioblastoma and mesothelioma.\"},{\"question\":\"How does MTAP deficiency create a therapeutic opportunity?\",\"answer\":\"MTAP loss causes MTA accumulation that outcompetes SAM for binding to PRMT5, altering PRMT5 activity. This creates selectivity for further PRMT5-pathway inhibition in MTAP-deleted tumor cells.\"},{\"question\":\"Why did earlier PRMT5-targeted treatments have safety limitations?\",\"answer\":\"They showed high rates of dose-limiting hematologic toxicities because they lacked selectivity for tumor cells.\"}]","MTAP Deletion in Oncogenesis - A Synthetic Lethality Scenario | PDF",1790118401,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4757c50d4a34e161f8c4b83e01eea709.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1495cd7166ff18dabb07441b66ac4d09.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c33dae379405fa660dd43a71a7fcbad.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1707826c62cedd2103b032944044bd5a.webp",980,1311]